Please login to the form below
Ongentys
This page shows the latest Ongentys news and features for those working in and with pharma, biotech and healthcare.
Neurocrine bags FDA approval for first tardive dyskinesia drug
The COMT inhibitor was approved in Europe as Ongentys last June as an adjunct to Parkinson's disease treatment, and Neurocrine is hoping to meet with the FDA to see what
Latest news
-
EC approves Bial’s Parkinson’s disease therapy
Manufactured by Bial, Ongentys (opicapone) is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adults with Parkinson's and end-of-dose motor fluctuations who cannot ... Bial says its drug will be
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
execute a successful virtual launch if it is going to compete with drugs such as Inbrija (Acorda Therapeutics), Nourianz (Kyowa Kirin), and Ongentys (Neurocrine Biosciences).
-
Deal Watch February 2017
Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- AZ sells stake in Moderna for around $1.2bn
- The role of women in science and technology
- Building meaningful customer engagement through data-driven digital insights
- Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
- Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA
- EMA recommends use of Lilly’s COVID-19 antibody cocktail
- Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise
- ZENO GROUP HIRES AVRIL LEE AS HEAD OF HEALTHCARE, U.K. AND EUROPE
- Choose to challenge for women’s health on this International Women's Day
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Choose to challenge for women’s health on this International Women's Day
- Today, you could be taking the time to reflect on the inspirational achievements of many women across the world. Or maybe you’re a woman yourself, and you want to take...
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Quick links
Infographics
